[2]
Dechant KL,Brogden RN,Pilkington T,Faulds D, Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 Sep;
[PubMed PMID: 1720382]
[3]
Kondagunta GV,Bacik J,Donadio A,Bajorin D,Marion S,Sheinfeld J,Bosl GJ,Motzer RJ, Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Sep 20;
[PubMed PMID: 16170162]
[4]
Noujaim J,Constantinidou A,Messiou C,Thway K,Miah A,Benson C,Judson I,Jones RL, Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. American journal of clinical oncology. 2018 Feb;
[PubMed PMID: 26523439]
[5]
Wagner MJ,Gopalakrishnan V,Ravi V,Livingston JA,Conley AP,Araujo D,Somaiah N,Zarzour MA,Ratan R,Wang WL,Patel SR,Lazar A,Ludwig JA,Benjamin RS, Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. The oncologist. 2017 Oct;
[PubMed PMID: 28710342]
[6]
Scandurra G,Scibilia G,Banna GL,D'Agate G,Lipari H,Gieri S,Scollo P, Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. Journal of gynecologic oncology. 2015 Apr;
[PubMed PMID: 25686397]
[7]
Siefker-Radtke AO,Dinney CP,Shen Y,Williams DL,Kamat AM,Grossman HB,Millikan RE, A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 1;
[PubMed PMID: 22914978]
Level 1 (high-level) evidence
[8]
Fukunaga A,Hyuga M,Iwasaki M,Nakae Y,Kishimoto W,Maesako Y,Arima N, Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Journal of clinical and experimental hematopathology : JCEH. 2016;
[PubMed PMID: 27334858]
[9]
Zhou Y,Xu Y,Zhao J,Zhong W,Wang M, [Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 2015 Jun;
[PubMed PMID: 26104891]
[10]
Basaran M,Bavbek ES,Saglam S,Eralp L,Sakar B,Atalar AC,Bilgic B,Ozger H,Onat H, A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007;
[PubMed PMID: 18185020]
[11]
Shin W,Lee HJ,Yang SJ,Paik ES,Choi HJ,Kim TJ,Choi CH,Lee JW,Bae DS,Kim BG, Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstetrics
[PubMed PMID: 29780777]
Level 2 (mid-level) evidence
[12]
Grassin F,Paleiron N,André M,Caliandro R,Bretel JJ,Terrier P,Margery J,Le Chevalier T,Ruffié P, Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Jun;
[PubMed PMID: 20521356]
[13]
Ifosfamide-Induced Malignancy of Ureter and Bladder., Sannu A,Radha R,Mathews A,Padmakumari Mony R,Prahladan A,James FV,, Cureus, 2017 Aug 22
[PubMed PMID: 29062626]
[14]
Voelcker G, Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anti-cancer drugs. 2018 Jan;
[PubMed PMID: 29219879]
[15]
Kerbusch T,de Kraker J,Keizer HJ,van Putten JW,Groen HJ,Jansen RL,Schellens JH,Beijnen JH, Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clinical pharmacokinetics. 2001 Jan;
[PubMed PMID: 11236809]
[16]
Kataria PS,Kendre PP,Patel AA, Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction. Journal of pharmacology & pharmacotherapeutics. 2017 Jan-Mar
[PubMed PMID: 28405136]
[17]
Shimada K,Hasegawa S,Nakao S,Mukai R,Matsumoto K,Tanaka M,Uranishi H,Masuta M,Nishida S,Shimizu S,Hayashi Y,Suzuki A,Nakamura M, Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. Cancer chemotherapy and pharmacology. 2019 Nov
[PubMed PMID: 31502115]
[19]
Dupuis LL,Boodhan S,Holdsworth M,Robinson PD,Hain R,Portwine C,O'Shaughnessy E,Sung L, Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatric blood
[PubMed PMID: 23512831]
[20]
Floyd JD,Nguyen DT,Lobins RL,Bashir Q,Doll DC,Perry MC, Cardiotoxicity of cancer therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Oct 20;
[PubMed PMID: 16234530]
[22]
Matz EL,Hsieh MH, Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology. 2017 Feb
[PubMed PMID: 27566144]
Level 3 (low-level) evidence
[24]
Kerbusch T,Jeuken MJ,Derraz J,van Putten JW,Huitema AD,Beijnen JH, Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection. Therapeutic drug monitoring. 2000 Oct;
[PubMed PMID: 11034269]
[25]
Kintzel PE,Dorr RT, Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer treatment reviews. 1995 Jan;
[PubMed PMID: 7859226]
[26]
Griggs JJ,Mangu PB,Anderson H,Balaban EP,Dignam JJ,Hryniuk WM,Morrison VA,Pini TM,Runowicz CD,Rosner GL,Shayne M,Sparreboom A,Sucheston LE,Lyman GH, Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 May 1;
[PubMed PMID: 22473167]
Level 1 (high-level) evidence
[28]
Turner AR,Duong CD,Good DJ, Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clinical oncology (Royal College of Radiologists (Great Britain)). 2003 Oct;
[PubMed PMID: 14570094]
[29]
Morgan LR,Harrison EF,Hawke JE,Hunter HL,Costanzi JJ,Plotkin D,Tucker WG,Worrall PM, Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Seminars in oncology. 1982 Dec;
[PubMed PMID: 7163813]
[30]
Loebstein R,Koren G, Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics. 1998 Jun;
[PubMed PMID: 9606250]
[31]
Kandylis K,Vassilomanolakis M,Tsoussis S,Efremidis AP, Ifosfamide cardiotoxicity in humans. Cancer chemotherapy and pharmacology. 1989;
[PubMed PMID: 2791194]